Following on from information provided to NICE by the company in April 2019 the appraisal of Lung cancer (non-small-cell, KRAS positive) - abemaciclib (after platinum chemotherapy) [ID1147] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1147 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in April 2019 the appraisal of Lung cancer (non-small-cell, KRAS positive) - abemaciclib (after platinum chemotherapy) [ID1147] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 08 May 2018 | Suspended. Please be advised that the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy. However, the company have advised that abemaciclib in this indication will no longer be progressing at this time. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred we will continue to monitor any development and will update interested parties if the situation changes. |
| 05 December 2017 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual